open access
Validation of the Polish version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
, 2, 3, 45, 6, 7, 8, 9, 3, 6, 10, 11, 45, 12, 13, 14, 15, 15, 1,
Affiliations- Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
- Department of Neurology and Regenerative Medicine, Dr Boczarska-Jedynak Health Institute, Oświęcim, Poland
- Department of Neurology, Wroclaw Medical University, Wroclaw, Poland
- Department of Neurological-Psychiatric Nursing, Medical University of Gdansk, Gdansk, Poland
- Neurology and Stroke Department, St. Adalbert Hospital, Gdańsk, Poland
- Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland
- Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland
- Department of Extrapyramidal Diseases, Medical University of Łódź, Łódź, Poland
- Department of Neurorehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
- Department of Neurology, Jagiellonian University, Collegium Medicum, Krakow, Poland
- Department of Neurology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
- Department of Biostatistics, Gilead Sciences, Inc., Foster City, California, Foster City, United States
- Department of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, United States
- National Centre of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain
- Department of Neurological Sciences, Rush University Medical Centre, Chicago, Illinois, United States
open access
Abstract
Introduction. In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson’s Disease (PD). We have translated and validated the Polish version of the MDS-UPDRS, explored its dimensionality, and compared it to the original English one. Methods. The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO. The back-translation was completed by colleagues fluent in both languages (Polish and English) who were not involved in the original translation, and was reviewed by members of the MDS Rating Scales Programme. Then the translated version of the MDS-UPDRS underwent cognitive pretesting, and the translation was modified based on the results. The final translation was approved as the Official Working Document of the MDS-UPDRS Polish version, and was tested on 355 Polish PD patients recruited at movement disorders centres all over Poland (at Katowice, Gdańsk, Łódź, Warsaw, Wrocław, and Kraków). Confirmatory and explanatory factor analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version. Results. The Polish version of the MDS-UPDRS showed satisfactory clinimetric properties. The internal consistency of the Polish version was satisfactory. In the confirmatory factor analysis, all four parts had greater than 0.90 comparative fit index (CFI) compared to the original English MDS-UPDRS. Explanatory factor analysis suggested that the Polish version differed from the English version only within an acceptable range. Conclusions and clinical implications. The Polish version of the MDS-UPDRS meets the requirements to be designated as the Official Polish Version of the MDS-UPDRS, and is available on the MDS web page. We strongly recommend using the MDS-UPDRS instead of the UPDRS for research purposes and in everyday clinical practice.
Abstract
Introduction. In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson’s Disease (PD). We have translated and validated the Polish version of the MDS-UPDRS, explored its dimensionality, and compared it to the original English one. Methods. The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO. The back-translation was completed by colleagues fluent in both languages (Polish and English) who were not involved in the original translation, and was reviewed by members of the MDS Rating Scales Programme. Then the translated version of the MDS-UPDRS underwent cognitive pretesting, and the translation was modified based on the results. The final translation was approved as the Official Working Document of the MDS-UPDRS Polish version, and was tested on 355 Polish PD patients recruited at movement disorders centres all over Poland (at Katowice, Gdańsk, Łódź, Warsaw, Wrocław, and Kraków). Confirmatory and explanatory factor analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version. Results. The Polish version of the MDS-UPDRS showed satisfactory clinimetric properties. The internal consistency of the Polish version was satisfactory. In the confirmatory factor analysis, all four parts had greater than 0.90 comparative fit index (CFI) compared to the original English MDS-UPDRS. Explanatory factor analysis suggested that the Polish version differed from the English version only within an acceptable range. Conclusions and clinical implications. The Polish version of the MDS-UPDRS meets the requirements to be designated as the Official Polish Version of the MDS-UPDRS, and is available on the MDS web page. We strongly recommend using the MDS-UPDRS instead of the UPDRS for research purposes and in everyday clinical practice.
Keywords
MDS-UPDRS, Parkinson’s Disease, rating scale, validation, translation
About this articleTitle
Validation of the Polish version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Research Paper
Pages
416-425
Published online
2020-07-08
Page views
2845
Article views/downloads
992
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2020;54(5):416-425.
Keywords
MDS-UPDRS
Parkinson’s Disease
rating scale
validation
translation
Authors
Joanna Siuda
Magdalena Boczarska-Jedynak
Sławomir Budrewicz
Jarosław Dulski
Monika Figura
Urszula Fiszer
Agata Gajos
Agnieszka Gorzkowska
Ewa Koziorowska-Gawron
Dariusz Koziorowski
Anna Krygowska-Wajs
Monika Rudzińska-Bar
Jarosław Sławek
Xuehan Ren
Sheng Luo
Pablo Martinez-Martin
Glenn Stebbins
Christopher G. Goetz
Grzegorz Opala
MDS-UPDRS Polish Validation Task Force
References (17)- Emamzadeh FN, Surguchov A. Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. Front Neurosci. 2018; 12: 612.
- Barc K, Kuźma-Kozakiewicz M. Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2019; 53(2): 99–112.
- Malec-Litwinowicz M, Plewka A, Plewka D, et al. The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease. Neurol Neurochir Pol. 2018; 52(2): 243–251.
- Fahn S, Elton RL, Members of, et al. Members of the UPDRS Develoment Committee. Unified Parkinson’s Disease rating scale. In:, , , , editors. Recent develoments in Parkinson’s disease, vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. : 153–164.
- Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15): 2129–2170.
- Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013; 260(1): 228–236.
- Goetz CG, Stebbins GT, Wang Lu, et al. IPMDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS. Mov Disord Clin Pract. 2014; 1(2): 97–101.
- Fowler FJ. Improving Survey Questions: Design and Evaluation. Applied Social Research Methods Series: 38. Thousand Oaks: Sage. : 1995.
- Muthen LK. and Muthen BO. M plus Version 7 User's Guide. Los Angeles, CA: Muthen. : Muthen.
- Hatcher L. Step-by-step approach to using the SAS system for factor analysis and structural equation modeling. 1994. SAS Inst. , Cary, NC. ; 73.
- Brown TA. Confirmatory factor analysis for applied research. New York: Guilford SAGE Publications, Inc. : 2006.
- Browne M. An Overview of Analytic Rotation in Exploratory Factor Analysis. Multivariate Behavioral Research. 2010; 36(1): 111–150.
- Gorsuch RL. Factor analysis. Second edition. Hillsdale, NJ: Lawrence Erlbaum Associations, Inc. : 1983.
- Gallagher DA, Goetz CG, Stebbins G, et al. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012; 27(1): 79–83.
- Goetz CG, Liu Y, Stebbins GT, et al. Gender-, age- and race/ethnicity-based Differential Item Functioning (DIF) analysis of MDS-UPDRS. Mov Disord. 2016; 31(12): 1865–1873.
- Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014; 21(3): 519–524.
- Balash Y, Korczyn AD, Knaani J, et al. Quality-of-life perception by Parkinson's disease patients and caregivers. Acta Neurol Scand. 2017; 136(2): 151–154.
